# A Double-Blind, Randomized, Placebo-Controlled Phase IIa Clinical Trial to Evaluate the Safety and Efficacy of DT2-SCT in Subjects With Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct06789302` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06789302](<https://clinicaltrials.gov/study/NCT06789302>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06789302

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 120 participants.

## Technical summary

Registry record NCT06789302. Randomized; double masking; primary purpose treatment. Start 2025-12 (anticipated); primary completion 2028-06 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 120 participants (planned count; ClinicalTrials.gov record NCT06789302, source copy `cardio:ctgov-nct06789302-2025-08-22`, retrieved 2026-10-26)
- Planned start: 2025-12 (anticipated) (ClinicalTrials.gov record NCT06789302, source copy `cardio:ctgov-nct06789302-2025-08-22`, retrieved 2026-10-26)
- Primary completion: 2028-06 (anticipated) (ClinicalTrials.gov record NCT06789302, source copy `cardio:ctgov-nct06789302-2025-08-22`, retrieved 2026-10-26)
- Completion: 2028-06 (anticipated) (ClinicalTrials.gov record NCT06789302, source copy `cardio:ctgov-nct06789302-2025-08-22`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06789302-2025-08-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Double-Blind, Randomized, Placebo-Controlled Phase IIa Clinical Trial to Evaluate the Safety and Efficacy of DT2-SCT in Subjects With Type 2 Diabetes Mellitus
- Condition: Type 2 Diabetes Mellitus (T2DM)
- Intervention (Drug): DT2-SCT intravenous infusion
- Intervention (Other): Placebo
- Lead sponsor: Global Institute of Stem Cell Therapy and Research
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: fa927f2c51fd6873cd65ba035057b4aa71a08c70104227b6cdd46324a76daba9
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
